‘Great potential’: Serum Institute begins production of 1st Covovax batch – Hindustan Times

US biotechnology company Novavax?s protein-based vaccine, NVX-CoV2373, has demonstrated 100% protection against moderate and severe disease, and 90.4% overall efficacy, in its Phase 3 trial. | Latest News India Read More